Active — Not RecruitingNot Applicable

A Genotype-Phenotype Urothelial Cancer Registry

United States3,519 participantsStarted 2009-05

Plain-language summary

This study is being done to create a registry to help us learn more about urinary and other cancers. This will let us look at large groups of people who do and do not have this kind of cancer. The investigators will look at risk factors to learn more about how these impact cancer. The investigators will also look at genetic markers. These are genes that are found in a known place. They are often associated with a particular trait. If the gene changes in some way, it may predict cancer or response to treatment. The investigators will look for markers in your saliva. This registry will help us develop better methods of: Preventing these cancers. Diagnosing these cancers. Treating these cancers.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Urothelial Cancer Cases * Must be ≥ 18 years of age AND * Must have a diagnosis of urothelial cancer AND * Must be an English-speaker Non-Cancer Control Group * Must be ≥ 18 years of age AND * Must not have cancer or a personal history of cancer, with the exception of skin cancer. AND * Must not be a blood relative of cases AND * Must not be a blood relative of another control AND * Must be an English-speaker Family Member Control Group: In select kindreds with a high prevalence of bladder cancer and/or very early onset bladder cancer, first- and second-degree family members of probands may be contacted by the MSKCC study team and invited to complete the questionnaire and submit a saliva sample. * Must be ≥ 18 years of age AND * Must be a blood relative of a case participant AND * Must be an English-speaker Exclusion Criteria: * Have any condition, which in the opinion of the primary MSKCC clinician or investigators precludes their ability to provide informed consent.

What they're measuring

Determine whether single nucleotide polymorphisms in regions discovered from whole genome scans, such as 8q24 & chromosome 3, & candidate genes, include NAT2 & GSTM1, prev found to be assoc with bladder ca risk, are assoc with UC in this study population

Timeframe: 2 years

Trial details

NCT IDNCT00902590

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05-31